NCT01022333View on ClinicalTrials.gov

The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers

PHASE1UnknownINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

December 31, 2010

Conditions
Breast Cancer
Interventions
DIETARY_SUPPLEMENT

Diindolylmethane (DIM)

300 mg per day of DIM for six weeks.

Trial Locations (1)

M5G 1N8

RECRUITING

Familial Breast Cancer Research Unit, Women's College Research Institute, Toronto

Sponsors

Collaborators (1)

BioResponse
All Listed Sponsors
collaborator

BioResponse

INDUSTRY

lead

Women's College Hospital

OTHER